Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice

• Published in: Diagnostics (Basel) Vol. 14; no. 6; p. 646
• Main Authors: Nishimura, Koichi, Kusunose, Masaaki, Shibayama, Ayumi, Nakayasu, Kazuhito
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.03.2024; MDPI
• Subjects: Chronic obstructive pulmonary disease; chronic obstructive pulmonary disease (COPD); Classification; Clinical medicine; COPD Assessment Test (CAT); disease severity; Geriatrics; Gerontology; Global Initiative for Chronic Obstructive Lung Disease (GOLD); Japan; Lung diseases, Obstructive; Mortality; Patients; St. George’s Respiratory Questionnaire (SGRQ); STaging of Airflow obstruction by Ratio (STAR); Japan; St. George’s Respiratory Questionnaire (SGRQ); COPD Assessment Test (CAT); disease severity; chronic obstructive pulmonary disease (COPD); STaging of Airflow obstruction by Ratio (STAR); Global Initiative for Chronic Obstructive Lung Disease (GOLD)
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics14060646

In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV /FVC ratio <0.70: STAR 1 ≥0.60 to <0.70, STAR 2 ≥0.50 to <0.60, STAR 3 ≥0.40 to <0.50, and STAR 4 <0.40. The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298-13.733), = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George's Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR.